| eTable 5. LS Means From MMRM for VAS for Efficacy Score for Days 1 to 7 Inclusive (mITT Population) |
| --- |
| Study Day | Placebo(n = 151) | Lofexidine HCl |
| 2.16 mg/day(n = 229) | 2.88 mg/day(n = 222) |
| LS Mean | LS Mean | *P* Value | LS Mean | *P* Value |
| Day 1 | 41.45 | 50.22 | .003 | 50.25 | .004 |
| Day 2 | 37.23 | 53.04 | <.001 | 56.77 | <.001 |
| Day 3 | 44.48 | 60.95 | <.001 | 62.60 | <.001 |
| Day 4 | 43.32 | 64.25 | <.001 | 68.94 | <.001 |
| Day 5 | 47.81 | 67.30 | <.001 | 70.19 | <.001 |
| Day 6 | 48.19 | 68.82 | <.001 | 76.26 | <.001 |
| Day 7 | 52.15 | 71.71 | <.001 | 78.11 | <.001 |
|  |
| VAS-E is subject-rated. Scores range from 0 to 100 with a higher score being favorable (0 mm = not effective at all, 100 mm = completely effective).HCl, hydrochloride; LS, least squares; mITT, modified intent-to-treat; MMRM, mixed model of repeated measures; VAS, visual analogue scale; VAS-E, visual analogue scale for efficacy. |